https://bio-exec-revamp.replit.app/assets/eric-vela-DoCERfwx.js

1import{j as e,S as s,N as r,L as i,m as t,F as n}from"./index-C4Gidzpw.js";import{v as c}from"./vela_1777912561870-BKHZoCPF.js";import{A as l}from"./arrow-left-CZk617bA.js";function p(){return e.jsxs("div",{className:"min-h-screen bg-background text-foreground overflow-x-hidden",children:[e.jsx(s,{title:"Eric Vela | BiotechExec",description:"View the executive profile and expertise of Eric Vela at BiotechExec."}),e.jsx(r,{}),e.jsx("section",{className:"pt-32 pb-24 relative",children:e.jsxs("div",{className:"container mx-auto px-6",children:[e.jsxs(i,{href:"/about",className:"inline-flex items-center gap-2 text-primary hover:text-primary/80 transition-colors mb-8",children:[e.jsx(l,{className:"w-4 h-4"}),"Back to Team"]}),e.jsx("div",{className:"max-w-4xl mx-auto",children:e.jsxs(t.div,{initial:{opacity:0,y:20},animate:{opacity:1,y:0},children:[e.jsxs("div",{className:"flex flex-col md:flex-row gap-8 items-center md:items-start mb-8 border-b border-white/5 pb-8",children:[e.jsx("div",{className:"w-40 h-40 md:w-48 md:h-48 flex-shrink-0 rounded-3xl overflow-hidden border-2 border-white/10 shadow-xl bg-card",children:e.jsx("img",{src:c,alt:"Eric Vela",width:218,height:218,loading:"eager",decoding:"async",className:"w-full h-full object-cover",onError:a=>{a.currentTarget.onerror=null,a.currentTarget.src="/images/team-avatar-fallback.svg"}})}),e.jsxs("div",{className:"flex-1 pt-2 md:pt-4 text-center md:text-left",children:[e.jsx("h1",{className:"font-serif text-4xl md:text-5xl font-bold text-white mb-3",children:"Eric Vela, PhD, MBA"}),e.jsx("h2",{className:"text-xl text-primary font-medium mb-4",children:"Principal"}),e.jsx("p",{className:"text-sm text-gray-400 font-medium uppercase tracking-wider mb-8",children:"Biotech CTO/CSO"})]})]}),e.jsxs("div",{className:"space-y-12",children:[e.jsxs("div",{className:"text-gray-300 leading-relaxed space-y-6 prose prose-invert prose-lg max-w-none",children:[e.jsx("p",{children:"Eric Vela, PhD, MBA has over two decades experience growing highly successful gene therapy and viral vaccine programs that have driven innovation and novel process development and manufacturing platforms leading to the launch of new products for phase I clinical vaccine and immunotherapy trials. He has a plethora of experience ranging from in vivo efficacy and pre-clinical testing to vaccine process development and manufacturing at various Contract Research Organizations (CROs), Contract Development and Manufacturing Organizations (CDMOs) and seed stage start-up companies."}),e.jsx("p",{children:"Throughout his career, Eric has played a pivotal role in chemistry, manufacturing, and controls (CMC) activities which is critical to developing and launching new pharmaceutical products. His leadership has led to the development of novel manufacturing processes aimed at improving the vaccine production and purification processes and optimizing overall yield. Specifically, Eric has C-suite experience that revolves around CMC as it relates to gene therapy, viral vaccine, and viral oncolytic products."})]}),e.jsxs("div",{className:"grid grid-cols-1 md:grid-cols-2 gap-8 items-start",children:[e.jsxs("div",{className:"bg-card/40 border border-white/5 rounded-3xl p-8 backdrop-blur-sm",children:[e.jsx("h3",{className:"font-serif text-xl text-white mb-6",children:"Career Accomplishments"}),e.jsxs("ul",{className:"space-y-3 text-gray-300 text-sm",children:[e.jsxs("li",{className:"flex gap-3",children:[e.jsx("span",{className:"text-primary mt-1.5",children:"•"}),e.jsx("span",{children:"Served as the Chief Technical Officer (CTO) for a startup gene therapy company based in Boston."})]}),e.jsxs("li",{className:"flex gap-3",children:[e.jsx("span",{className:"text-primary mt-1.5",children:"•"}),e.jsx("span",{children:"Led all manufacturing and process development activities associated with an AAV (Adeno-associated virus) novel capsid gene therapy technology associated with central nervous system (CNS) rare diseases and primary CNS lymphoma (PCNSL)."})]}),e.jsxs("li",{className:"flex gap-3",children:[e.jsx("span",{className:"text-primary mt-1.5",children:"•"}),e.jsx("span",{children:"Served as a Chief Technology Advisor for different c

1ompanies with gene therapy and oncolytic virotherapy products."})]}),e.jsxs("li",{className:"flex gap-3",children:[e.jsx("span",{className:"text-primary mt-1.5",children:"•"}),e.jsx("span",{children:"Served as the Executive Director for Process Development at a CDMO where he was responsible from expanding a team of 10 scientists and engineers to a team of 42 responsible for upstream and downstream operations ranging from small-scale bioreactors to a 1,000 L bioreactor in scale."})]}),e.jsxs("li",{className:"flex gap-3",children:[e.jsx("span",{className:"text-primary mt-1.5",children:"•"}),e.jsx("span",{children:"Has process development and manufacturing production and purification experience in different therapeutic modalities including gene therapy vectors, oncolytic viruses, viral-based vaccines, antibodies, and proteins."})]}),e.jsxs("li",{className:"flex gap-3",children:[e.jsx("span",{className:"text-primary mt-1.5",children:"•"}),e.jsx("span",{children:"Served as the Director of Virology at a Contract Research Organization (CRO) and was responsible for more than 50 GLP efficacy and tox nonhuman primate and small-mammal preclinical studies."})]}),e.jsxs("li",{className:"flex gap-3",children:[e.jsx("span",{className:"text-primary mt-1.5",children:"•"}),e.jsx("span",{children:"Built and cultivated relationships with pharmaceutical companies and the Federal Drug Administration that contributed to increasing the CRO virology program's yearly business volume from $1-2M to $8-12M."})]})]})]}),e.jsxs("div",{className:"bg-card/40 border border-white/5 rounded-3xl p-8 backdrop-blur-sm",children:[e.jsx("h3",{className:"font-serif text-xl text-white mb-6",children:"Areas of Excellence"}),e.jsxs("div",{className:"space-y-3",children:[e.jsxs("div",{className:"flex gap-3 text-gray-300 text-sm",children:[e.jsx("span",{className:"text-primary mt-1.5",children:"•"}),e.jsx("span",{children:"Viral vaccines and therapeutics and production modalities"})]}),e.jsxs("div",{className:"flex gap-3 text-gray-300 text-sm",children:[e.jsx("span",{className:"text-primary mt-1.5",children:"•"}),e.jsx("span",{children:"Gene therapy products and production modalities"})]}),e.jsxs("div",{className:"flex gap-3 text-gray-300 text-sm",children:[e.jsx("span",{className:"text-primary mt-1.5",children:"•"}),e.jsx("span",{children:"Oncolytic virotherapies"})]}),e.jsxs("div",{className:"flex gap-3 text-gray-300 text-sm",children:[e.jsx("span",{className:"text-primary mt-1.5",children:"•"}),e.jsx("span",{children:"Process development and CGMP manufacturing"})]}),e.jsxs("div",{className:"flex gap-3 text-gray-300 text-sm",children:[e.jsx("span",{className:"text-primary mt-1.5",children:"•"}),e.jsx("span",{children:"Vector design"})]}),e.jsxs("div",{className:"flex gap-3 text-gray-300 text-sm",children:[e.jsx("span",{className:"text-primary mt-1.5",children:"•"}),e.jsx("span",{children:"Upstream production and downstream purification modalities"})]}),e.jsxs("div",{className:"flex gap-3 text-gray-300 text-sm",children:[e.jsx("span",{className:"text-primary mt-1.5",children:"•"}),e.jsx("span",{children:"Transferring small-scale production/purification modalities to large-scale CGMP manufacturing"})]}),e.jsxs("div",{className:"flex gap-3 text-gray-300 text-sm",children:[e.jsx("span",{className:"text-primary mt-1.5",children:"•"}),e.jsx("span",{children:"Bioreactor development"})]}),e.jsxs("div",{className:"flex gap-3 text-gray-300 text-sm",children:[e.jsx("span",{className:"text-primary mt-1.5",children:"•"}),e.jsx("span",{children:"Strategic planning"})]}),e.jsxs("div",{className:"flex gap-3 text-gray-300 text-sm",children:[e.jsx("span",{className:"text-primary mt-1.5",children:"•"}),e.jsx("span",{children:"CDMO management"})]})]})]})]})]})]})})]})}),e.jsx(n,{})]})}export{p as default};